Molecular diagnostics firm Biocartis won a €750,000 grant (approximately $796,000) from the Flanders Organization for Innovation & Entrepreneurship (VLAIO) to support the development of a fully ...
New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies, and can guide treatment decisions for patients with Lynch-associated cancers LEIDEN, Netherlands & ...
Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies Mechelen, Belgium, 12 March 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an ...
Validity of 1% Hormonal Receptor Positivity Cutoff by the ASCO/College of American Pathologists Guidelines at the Georgia Cancer Center In 658 patients with advanced GI cancers who underwent both ...
CHICAGO — Patients found to have tumors with high microsatellite instability (MSI-H) should be tested and screened for Lynch syndrome, regardless what type of cancer they have, says an expert ...
First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback